H.C. Wainwright analyst Edward White removed the firm’s prior $1 price target on Aeglea BioTherapeutics following the "discouraging" interim results for pegtarviliase in classical homocystinuria. The firm only had a 20% probability of success for pegtarviliase in its model. Aeglea is now exploring strategic alternatives following the Phase 1/2 results for pegtarviliase.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGLE:
- Aeglea BioTherapeutics exploring strategic alternatives
- Aeglea BioTherapeutics announces interim Phase 1/2 results of pegtarviliase
- Aeglea BioTherapeutics reports Q4 revenue $200K, consensus $60K
- Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates
